Several recent clinical studies revealed a link between the reduced alpha diversity and the anti-PD1 response rate in patients with lung cancer.20 We next asked whether the improved anti-tumor immune response in mice treated with CBM588 is associated with specific changes in the fecal composition of bacteria. This evidence concerns the gene PDCD1 and lung carcinoma.